ClinicalTrials.gg
Not yet recruitingNCT05105399Updated Nov 12, 2026

Evaluation of Serratus Plane Block on the Respiratory Pattern in Patients With Multiple Rib Fractures

An interventional study of Serratus plane block (continuous or single-shot) in Rib Fractures and Spirometry, sponsored by Niguarda Hospital. Not yet recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Niguarda Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 12, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Sex
All
01

Study summary

In patients admitted following a trauma, the incidence of multiple rib fractures is reported to be 9,7%, and this can be even higher in high energy trauma like motor vehicle accidents (1). Pain deriving from rib fractures cause the patient to breath shallow in order to limit discomfort and this bring about negative consequences: shallow breathing and inability to clear secretions may cause pulmonary atelectasis eventually evolving to pneumonia. Given the aforementioned concerns, it is easy to understand why, in a context like this, control of chest pain become crucial. The best way to achieve adequate pain control have not yet been established: the aim of this study is to investigate on this clinical dilemma. In this study, 72 people with at least two monolateral rib fractures are going to be randomized into three groups: 1) standard treatment alone (intravenous analgesia: acetaminophen + morphine PCA); 2) continuous serratus plane block + standard treatment; 3) single-shot serratus plane block + standard treatment. The variables that are going to be recorded are the following: pain through the NRS scale, FEV1 and FVC through spirometry and finally an arterious gas analysis. Recording are going to be repeated at 72h after admission. The primary endpoint is to evaluate if the continuous serratus plane block is able to improve the FEV1/FVC compared to single shot or standard treatment alone. Secondary endpoints will be: the effect of continuous block on 1) resting and incident pain; 2) opioid consumption; 3) blood gas analysis parameters; 4) pulmonary complications at 1 month; 5) length of stay

02

Conditions studied

  • Rib Fractures
  • Spirometry

Browse trials for

03

In context

Rib Fractures

126 studies on the registry are indexed under Rib Fractures; 28 are open to participants now.

This study's planned enrollment of 72 is above the median of 60 across 92 interventional studies indexed under Rib Fractures.

Browse Rib Fractures studies →

Lead sponsor

Niguarda Hospital is the lead sponsor of 68 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Chest trauma with at least 2 monolateral rib fractures (monofocal or multifocal) with no flail chest
  2. Age>18 years
  3. Hospital admission
  4. Ability to provide written informed consensus
  5. Awake patient, spontaneous ventilation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • No intervention
    Morphine
  • Active comparator
    Continuous

    Procedure: Serratus plane block (continuous or single-shot)

  • Active comparator
    Single

    Procedure: Serratus plane block (continuous or single-shot)

Interventions

  • ProcedureSerratus plane block (continuous or single-shot)

    Patients assigned to the interventional arms will receive either continuous serratus plane block or single-shot serratus plane block

06

What researchers measure

Primary outcomes

  1. FEV1 (% of the predicted value)

    Any statistically significant difference between the two treatment groups and the control group will be measured. FEV1 is expected to be respectively 80±15% of the predicted value in the treatment groups and 64±15% of the predicted value in the control group

    Time frame: 72 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2027; primary completion for Dec 2027, 6 months later.

Of 41 non-industry interventional studies with no phase under Rib Fractures, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's planned 6 months is below that.

Counting every sponsor, half of 41 studies reached it within 23 months; a quarter within 15 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Jun 2026 → Jun 2027, primary completion Dec 2026 → Dec 2027 and completion May 2027 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2021
First posted
Nov 3, 2021
StartEst.
Jun 1, 2027was Jun 2026
Primary completionEst.
Dec 1, 2027was Dec 2026
CompletionEst.
May 1, 2028was May 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 1, 2026→Jun 1, 2027
Nov 12, 2026
Primary completion
Dec 1, 2026→Dec 1, 2027
Nov 12, 2026
Study completion
May 1, 2027→May 1, 2028
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date Jun 1, 2026→Jun 1, 2027
    Primary completion Dec 1, 2026→Dec 1, 2027
    Study completion May 1, 2027→May 1, 2028

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05105399
Lead sponsor
Niguarda Hospital
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Jun 1, 2027 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Antonio Giorgi, MD
Contact
antonio.giorgi@ospdaleniguarda.it
+393208588471

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion